Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Taxes (2021 - 2026)

Indivior Pharmaceuticals has reported Current Taxes over the past 6 years, most recently at $26.0 million for Q1 2026.

  • For Q1 2026, Current Taxes rose 116.67% year-over-year to $26.0 million; the TTM value through Mar 2026 reached $26.0 million, up 116.67%, while the annual FY2025 figure was $2.0 million, 71.43% down from the prior year.
  • Current Taxes for Q1 2026 was $26.0 million at Indivior Pharmaceuticals, up from $2.0 million in the prior quarter.
  • Over five years, Current Taxes peaked at $26.0 million in Q1 2026 and troughed at -$9.0 million in Q3 2024.
  • A 5-year average of $3.9 million and a median of $4.0 million in 2025 define the central range for Current Taxes.
  • Biggest five-year swings in Current Taxes: plummeted 80.0% in 2024 and later soared 312.5% in 2025.
  • Year by year, Current Taxes stood at $9.0 million in 2022, then dropped by 11.11% to $8.0 million in 2023, then dropped by 12.5% to $7.0 million in 2024, then crashed by 71.43% to $2.0 million in 2025, then soared by 1200.0% to $26.0 million in 2026.
  • Business Quant data shows Current Taxes for INDV at $26.0 million in Q1 2026, $2.0 million in Q4 2025, and $4.0 million in Q3 2025.